Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T17:32:16.883Z.
Calculation as of: 2026-10-06T17:32:16.883Z.
Quote observation: 2026-10-06T17:29:49.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e5bf89a371f0468543faa328a941ad2f1c46577ddea7987f626d68fdce73ba7d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$8.36M
EV/FCF Ratio
N/A
TTM Avg
12.59x
3Y Avg
12.59x
5Y Avg
12.59x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| HeartSciences Inc. (HSCS) | $8.18M | N/A | N/A | N/A | N/A |
| Aprea Therapeutics, Inc. (APRE)vs › | $8.13M | N/A | N/A | N/A | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.36M | N/A | 12.59x | 12.59x | 12.59x |
| GT Biopharma, Inc. (GTBP)vs › | $7.95M | N/A | N/A | N/A | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $8.01M | N/A | N/A | N/A | N/A |
| Traws Pharma, Inc. (TRAW)vs › | $7.93M | N/A | N/A | N/A | N/A |
| DataMEDS AI, Inc. (MEDS)vs › | $8.53M | N/A | N/A | N/A | N/A |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.81M | N/A | N/A | N/A | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.43M | N/A | N/A | N/A | N/A |
| Skye Bioscience, Inc. (SKYE)vs › | $7.25M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
